Symbols / NRSN $0.70 +1.78% NeuroSense Therapeutics Ltd.
NRSN Chart
About
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel.
Fundamentals
Scroll to Statements| Market Cap | 24.83M | Enterprise Value | 24.83M | Income | -11.12M | Sales | — | Book/sh | -0.05 | Cash/sh | 0.01 |
| Dividend Yield | — | Payout | 0.00% | Employees | 17 | IPO | — | P/E | — | Forward P/E | -1.39 |
| PEG | — | P/S | — | P/B | -14.63 | P/C | — | EV/EBITDA | -2.24 | EV/Sales | — |
| Quick Ratio | 0.08 | Current Ratio | 0.31 | Debt/Eq | — | LT Debt/Eq | — | EPS (ttm) | -0.44 | EPS next Y | -0.51 |
| EPS Growth | — | Revenue Growth | — | Earnings | 2025-04-07 | ROA | -247.30% | ROE | -21.75% | ROIC | — |
| Gross Margin | 0.00% | Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 35.35M | Shs Float | 26.03M | Short Float | 2.18% |
| Short Ratio | 3.33 | Short Interest | — | 52W High | 2.60 | 52W Low | 0.63 | Beta | 1.68 | Avg Volume | 158.72K |
| Volume | 94.47K | Target Price | $8.38 | Recom | Strong_buy | Prev Close | $0.69 | Price | $0.70 | Change | 1.78% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$8.38
Mean price target
2. Current target
$0.70
Latest analyst target
3. DCF / Fair value
$-1.97
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.70
Low
$3.00
High
$14.00
Mean
$8.38
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-04-08 | main | D. Boral Capital | Buy → Buy | $14 |
| 2026-03-25 | main | D. Boral Capital | Buy → Buy | $14 |
| 2026-03-17 | main | D. Boral Capital | Buy → Buy | $14 |
| 2026-03-10 | init | Roth Capital | — → Buy | $3 |
| 2026-03-09 | main | D. Boral Capital | Buy → Buy | $14 |
| 2025-12-22 | main | D. Boral Capital | Buy → Buy | $14 |
| 2025-11-24 | main | D. Boral Capital | Buy → Buy | $14 |
| 2025-08-15 | main | D. Boral Capital | Buy → Buy | $14 |
| 2025-07-10 | main | D. Boral Capital | Buy → Buy | $14 |
| 2025-05-12 | init | D. Boral Capital | — → Buy | $14 |
| 2024-12-16 | down | Maxim Group | Buy → Hold | — |
- ALS drug showed 65% lower death risk; NeuroSense ended 2025 with $166,000 cash - Stock Titan ue, 31 Mar 2026 07
- NEUROSENSE THERAPEUTICS LTD (NRSN) Earnings History & Surprises - ChartMill Fri, 17 Apr 2026 07
- NeuroSense Therapeutics Announces $500,000 Private Placement at Premium to Market Price - PR Newswire hu, 04 Sep 2025 07
- NRSN Analyst Rating Update: D. Boral Capital Maintains 'Buy' Rat - GuruFocus Wed, 08 Apr 2026 13
- ALS drug candidate heads to Copenhagen as NeuroSense advances Phase 3 - Stock Titan Wed, 18 Mar 2026 07
- NeuroSense keeps Nasdaq listing for now after 2 compliance notices - Stock Titan Fri, 03 Apr 2026 07
- If You Invested $1,000 in Neurosense Therapeutics Ltd (NRSN) - Stock Titan Sun, 22 Mar 2026 13
- Brazil grants NeuroSense ALS drug patent protection through 2042 - Stock Titan Mon, 06 Apr 2026 07
- NeuroSense Therapeutics (NRSN) director details options and restricted shares - Stock Titan ue, 31 Mar 2026 07
- NeuroSense (NRSN) CFO awarded 200,000 restricted shares vesting over 2 years - Stock Titan Wed, 01 Apr 2026 07
- NeuroSense (NRSN) CFO Or Eisenberg reports 573,126 shares and warrants on Form 3 - Stock Titan Wed, 01 Apr 2026 07
- Nasdaq flags NeuroSense (NRSN) for bid price and $35M value shortfall - Stock Titan Fri, 03 Apr 2026 07
- NeuroSense (NRSN) CTO awarded 200,000 restricted shares vesting over two years - Stock Titan Mon, 30 Mar 2026 07
- NeuroSense (NRSN) CEO details substantial share and warrant holdings - Stock Titan Mon, 30 Mar 2026 07
- NeuroSense delays Canada meeting to add data as Alzheimer’s results near - Stock Titan ue, 24 Mar 2026 07
Financials
Statement View
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Expense |
|
11.09
+11.95%
|
9.90
-17.82%
|
12.05
+14.17%
|
10.55
|
| Research And Development |
|
6.23
+9.28%
|
5.70
-21.67%
|
7.27
+30.20%
|
5.59
|
| Selling General And Administration |
|
4.86
+15.56%
|
4.20
-11.96%
|
4.78
-3.87%
|
4.97
|
| General And Administrative Expense |
|
4.86
+15.56%
|
4.20
-11.96%
|
4.78
-3.87%
|
4.97
|
| Salaries And Wages |
|
1.81
+47.19%
|
1.23
-37.71%
|
1.97
-9.16%
|
2.17
|
| Other Gand A |
|
2.76
+3.53%
|
2.67
+16.37%
|
2.29
+41.33%
|
1.62
|
| Total Expenses |
|
11.09
+11.95%
|
9.90
-17.82%
|
12.05
+14.17%
|
10.55
|
| Operating Income |
|
-11.09
-11.95%
|
-9.90
+17.82%
|
-12.05
-14.17%
|
-10.55
|
| Total Operating Income As Reported |
|
-11.09
-11.95%
|
-9.90
+17.82%
|
-12.05
-14.17%
|
-10.55
|
| EBITDA |
|
-11.07
-12.03%
|
-9.88
+17.86%
|
-12.03
-14.10%
|
-10.54
|
| Normalized EBITDA |
|
-11.02
-11.55%
|
-9.88
+30.61%
|
-14.24
-35.36%
|
-10.52
|
| Reconciled Depreciation |
|
0.02
-27.27%
|
0.02
+4.76%
|
0.02
+75.00%
|
0.01
|
| EBIT |
|
-11.09
-11.95%
|
-9.90
+17.82%
|
-12.05
-14.17%
|
-10.55
|
| Total Unusual Items |
|
-0.05
-4800.00%
|
0.00
-99.95%
|
2.21
+10154.55%
|
-0.02
|
| Total Unusual Items Excluding Goodwill |
|
-0.05
-4800.00%
|
0.00
-99.95%
|
2.21
+10154.55%
|
-0.02
|
| Net Income |
|
-11.12
-8.96%
|
-10.21
-1.02%
|
-10.11
+3.67%
|
-10.49
|
| Pretax Income |
|
-11.12
-8.96%
|
-10.21
-1.02%
|
-10.11
+3.67%
|
-10.49
|
| Net Non Operating Interest Income Expense |
|
0.01
+102.27%
|
-0.31
-14.44%
|
-0.27
-421.43%
|
0.08
|
| Interest Expense Non Operating |
|
—
|
—
|
0.01
-26.67%
|
0.01
|
| Net Interest Income |
|
0.01
+102.27%
|
-0.31
-14.44%
|
-0.27
-421.43%
|
0.08
|
| Interest Expense |
|
—
|
—
|
0.01
-26.67%
|
0.01
|
| Interest Income Non Operating |
|
0.01
+550.00%
|
0.00
-98.88%
|
0.18
+95.60%
|
0.09
|
| Interest Income |
|
0.01
+550.00%
|
0.00
-98.88%
|
0.18
+95.60%
|
0.09
|
| Other Income Expense |
|
-0.05
-4800.00%
|
0.00
-99.95%
|
2.21
+10154.55%
|
-0.02
|
| Gain On Sale Of Security |
|
-0.05
-4800.00%
|
0.00
-99.95%
|
2.21
+10154.55%
|
-0.02
|
| Tax Rate For Calcs |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-11.12
-8.96%
|
-10.21
-1.02%
|
-10.11
+3.67%
|
-10.49
|
| Net Income From Continuing Operation Net Minority Interest |
|
-11.12
-8.96%
|
-10.21
-1.02%
|
-10.11
+3.67%
|
-10.49
|
| Net Income From Continuing And Discontinued Operation |
|
-11.12
-8.96%
|
-10.21
-1.02%
|
-10.11
+3.67%
|
-10.49
|
| Net Income Continuous Operations |
|
-11.12
-8.96%
|
-10.21
-1.02%
|
-10.11
+3.67%
|
-10.49
|
| Normalized Income |
|
-11.08
-8.49%
|
-10.21
+17.11%
|
-12.32
-17.66%
|
-10.47
|
| Net Income Common Stockholders |
|
-11.12
-8.96%
|
-10.21
-1.02%
|
-10.11
+3.67%
|
-10.49
|
| Diluted EPS |
|
-0.44
+18.52%
|
-0.54
+27.03%
|
-0.74
+18.68%
|
-0.91
|
| Basic EPS |
|
-0.44
+18.52%
|
-0.54
+27.03%
|
-0.74
+18.68%
|
-0.91
|
| Basic Average Shares |
|
25.48
+34.77%
|
18.91
+38.62%
|
13.64
+18.56%
|
11.50
|
| Diluted Average Shares |
|
25.48
+34.77%
|
18.91
+38.62%
|
13.64
+18.56%
|
11.50
|
| Diluted NI Availto Com Stockholders |
|
-11.12
-8.96%
|
-10.21
-1.02%
|
-10.11
+3.67%
|
-10.49
|
| Insurance And Claims |
|
0.29
-6.47%
|
0.31
-39.53%
|
0.51
-56.47%
|
1.17
|
| Total Other Finance Cost |
|
0.01
-98.07%
|
0.31
-30.58%
|
0.45
+6300.00%
|
0.01
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Assets |
|
1.03
-77.53%
|
4.58
+43.64%
|
3.19
-58.69%
|
7.71
|
| Current Assets |
|
0.78
-82.33%
|
4.40
+50.96%
|
2.92
-60.49%
|
7.38
|
| Cash Cash Equivalents And Short Term Investments |
|
0.17
-95.09%
|
3.38
+27.95%
|
2.64
-62.76%
|
7.09
|
| Cash And Cash Equivalents |
|
0.17
-95.09%
|
3.38
+27.95%
|
2.64
-25.49%
|
3.54
|
| Cash Financial |
|
—
|
—
|
—
|
—
|
| Other Short Term Investments |
|
—
|
—
|
0.00
-100.00%
|
3.55
|
| Receivables |
|
0.03
-79.88%
|
0.16
-1.20%
|
0.17
+26.72%
|
0.13
|
| Other Receivables |
|
0.03
-79.88%
|
0.16
-1.20%
|
0.17
+26.72%
|
0.13
|
| Prepaid Assets |
|
0.53
-35.52%
|
0.82
+1078.57%
|
0.07
-43.55%
|
0.12
|
| Restricted Cash |
|
0.05
+34.29%
|
0.04
-12.50%
|
0.04
+11.11%
|
0.04
|
| Total Non Current Assets |
|
0.25
+44.51%
|
0.17
-35.69%
|
0.27
-18.24%
|
0.33
|
| Net PPE |
|
0.23
+52.00%
|
0.15
-39.27%
|
0.25
-19.28%
|
0.31
|
| Gross PPE |
|
0.30
+44.76%
|
0.21
-26.32%
|
0.28
-11.76%
|
0.32
|
| Accumulated Depreciation |
|
-0.08
-26.67%
|
-0.06
-57.89%
|
-0.04
-123.53%
|
-0.02
|
| Properties |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Buildings And Improvements |
|
0.17
+102.38%
|
0.08
-48.15%
|
0.16
-29.26%
|
0.23
|
| Machinery Furniture Equipment |
|
0.13
+6.50%
|
0.12
+2.50%
|
0.12
+31.87%
|
0.09
|
| Other Properties |
|
—
|
—
|
—
|
0.23
|
| Leases |
|
0.00
+0.00%
|
0.00
+0.00%
|
0.00
+0.00%
|
0.00
|
| Other Non Current Assets |
|
0.02
-4.35%
|
0.02
+4.55%
|
0.02
-4.35%
|
0.02
|
| Total Liabilities Net Minority Interest |
|
2.59
+29.92%
|
1.99
-59.71%
|
4.94
+136.44%
|
2.09
|
| Current Liabilities |
|
2.52
+26.31%
|
1.99
-42.41%
|
3.46
+100.41%
|
1.73
|
| Payables And Accrued Expenses |
|
2.42
+26.00%
|
1.92
-43.39%
|
3.39
+162.38%
|
1.29
|
| Payables |
|
0.80
-31.12%
|
1.16
-20.49%
|
1.46
+192.97%
|
0.50
|
| Accounts Payable |
|
0.80
-31.12%
|
1.16
-20.49%
|
1.46
+192.97%
|
0.50
|
| Current Accrued Expenses |
|
1.62
+113.31%
|
0.76
-60.69%
|
1.93
+143.20%
|
0.79
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
—
|
—
|
0.21
-43.51%
|
0.37
|
| Current Debt And Capital Lease Obligation |
|
0.10
+34.25%
|
0.07
+5.80%
|
0.07
+7.81%
|
0.06
|
| Current Capital Lease Obligation |
|
0.10
+34.25%
|
0.07
+5.80%
|
0.07
+7.81%
|
0.06
|
| Total Non Current Liabilities Net Minority Interest |
|
0.07
|
0.00
-100.00%
|
1.49
+306.85%
|
0.36
|
| Long Term Debt And Capital Lease Obligation |
|
0.07
|
0.00
-100.00%
|
0.07
-50.34%
|
0.15
|
| Long Term Capital Lease Obligation |
|
0.07
|
0.00
-100.00%
|
0.07
-50.34%
|
0.15
|
| Stockholders Equity |
|
-1.56
-160.39%
|
2.58
+246.84%
|
-1.76
-131.30%
|
5.62
|
| Common Stock Equity |
|
-1.56
-160.39%
|
2.58
+246.84%
|
-1.76
-131.30%
|
5.62
|
| Capital Stock |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Common Stock |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Share Issued |
|
32.56
+40.16%
|
23.23
+51.04%
|
15.38
+30.53%
|
11.78
|
| Ordinary Shares Number |
|
32.56
+40.16%
|
23.23
+51.04%
|
15.38
+30.53%
|
11.78
|
| Additional Paid In Capital |
|
46.23
+17.79%
|
39.24
+61.08%
|
24.36
-7.74%
|
26.41
|
| Retained Earnings |
|
-47.78
-30.35%
|
-36.66
-40.35%
|
-26.12
-25.67%
|
-20.79
|
| Total Equity Gross Minority Interest |
|
-1.56
-160.39%
|
2.58
+246.84%
|
-1.76
-131.30%
|
5.62
|
| Total Capitalization |
|
-1.56
-160.39%
|
2.58
+246.84%
|
-1.76
-131.30%
|
5.62
|
| Working Capital |
|
-1.74
-172.12%
|
2.41
+543.83%
|
-0.54
-109.60%
|
5.66
|
| Invested Capital |
|
-1.56
-160.39%
|
2.58
+246.84%
|
-1.76
-131.30%
|
5.62
|
| Total Debt |
|
0.17
+132.88%
|
0.07
-48.59%
|
0.14
-32.70%
|
0.21
|
| Capital Lease Obligations |
|
0.17
+132.88%
|
0.07
-48.59%
|
0.14
-32.70%
|
0.21
|
| Net Tangible Assets |
|
-1.56
-160.39%
|
2.58
+246.84%
|
-1.76
-131.30%
|
5.62
|
| Tangible Book Value |
|
-1.56
-160.39%
|
2.58
+246.84%
|
-1.76
-131.30%
|
5.62
|
| Derivative Product Liabilities |
|
—
|
0.00
-100.00%
|
1.41
+547.71%
|
0.22
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-7.67
+24.31%
|
-10.13
-21.32%
|
-8.35
-9.69%
|
-7.62
|
| Cash Flow From Continuing Operating Activities |
|
-7.67
+24.31%
|
-10.13
-21.32%
|
-8.35
-9.69%
|
-7.62
|
| Net Income From Continuing Operations |
|
-11.12
-8.96%
|
-10.21
-1.02%
|
-10.11
+3.67%
|
-10.49
|
| Depreciation Amortization Depletion |
|
0.02
-27.27%
|
0.02
+4.76%
|
0.02
+75.00%
|
0.01
|
| Depreciation |
|
0.02
-27.27%
|
0.02
+4.76%
|
0.02
+75.00%
|
0.01
|
| Depreciation And Amortization |
|
0.02
-27.27%
|
0.02
+4.76%
|
0.02
+75.00%
|
0.01
|
| Other Non Cash Items |
|
-0.05
-114.24%
|
0.32
-31.71%
|
0.47
+1053.66%
|
0.04
|
| Stock Based Compensation |
|
2.14
+284.20%
|
0.56
-63.76%
|
1.54
-11.05%
|
1.73
|
| Operating Gains Losses |
|
—
|
-0.05
+97.90%
|
-2.19
-87.91%
|
-1.17
|
| Gain Loss On Investment Securities |
|
—
|
-0.05
+97.90%
|
-2.19
-87.91%
|
-1.17
|
| Gain Loss On Sale Of PPE |
|
—
|
—
|
0.00
|
0.00
|
| Change In Working Capital |
|
1.34
+272.09%
|
-0.78
-140.83%
|
1.91
+74.70%
|
1.09
|
| Change In Receivables |
|
—
|
—
|
0.02
-65.45%
|
0.06
|
| Change In Payables And Accrued Expense |
|
0.91
+2556.76%
|
-0.04
-101.96%
|
1.89
+77.37%
|
1.06
|
| Change In Payable |
|
0.91
+2556.76%
|
-0.04
-101.96%
|
1.89
+77.37%
|
1.06
|
| Change In Account Payable |
|
-0.36
-20.74%
|
-0.30
-131.11%
|
0.96
+109.37%
|
0.46
|
| Change In Other Current Assets |
|
0.51
+175.26%
|
-0.68
-825.81%
|
0.09
-25.60%
|
0.12
|
| Change In Other Current Liabilities |
|
-0.07
-5.80%
|
-0.07
+0.00%
|
-0.07
+27.37%
|
-0.10
|
| Investing Cash Flow |
|
-0.01
-900.00%
|
0.00
-99.97%
|
3.47
+196.60%
|
-3.59
|
| Cash Flow From Continuing Investing Activities |
|
-0.01
-900.00%
|
0.00
-99.97%
|
3.47
+196.60%
|
-3.59
|
| Net PPE Purchase And Sale |
|
-0.01
-166.67%
|
-0.00
+89.66%
|
-0.03
+58.57%
|
-0.07
|
| Purchase Of PPE |
|
-0.01
-166.67%
|
-0.00
+89.66%
|
-0.03
+58.57%
|
-0.07
|
| Capital Expenditure |
|
-0.01
-166.67%
|
-0.00
+89.66%
|
-0.03
+58.57%
|
-0.07
|
| Net Investment Purchase And Sale |
|
0.00
|
0.00
-100.00%
|
3.50
+200.00%
|
-3.50
|
| Purchase Of Investment |
|
—
|
—
|
—
|
-3.50
|
| Net Other Investing Changes |
|
—
|
0.00
+233.33%
|
-0.00
+85.00%
|
-0.02
|
| Financing Cash Flow |
|
4.43
-59.39%
|
10.91
+174.54%
|
3.98
+5.33%
|
3.77
|
| Cash Flow From Continuing Financing Activities |
|
4.43
-59.39%
|
10.91
+174.54%
|
3.98
+5.33%
|
3.77
|
| Net Issuance Payments Of Debt |
|
—
|
—
|
-0.08
-1.27%
|
-0.08
|
| Repayment Of Debt |
|
—
|
—
|
-0.08
-1.27%
|
-0.08
|
| Long Term Debt Payments |
|
—
|
—
|
-0.08
-1.27%
|
-0.08
|
| Net Long Term Debt Issuance |
|
—
|
—
|
-0.08
-1.27%
|
-0.08
|
| Net Common Stock Issuance |
|
4.53
-59.92%
|
11.30
+160.82%
|
4.33
|
0.00
|
| Proceeds From Stock Option Exercised |
|
0.02
|
0.00
-100.00%
|
0.01
-99.87%
|
3.77
|
| Net Other Financing Charges |
|
-0.12
+69.05%
|
-0.39
-7.42%
|
-0.36
|
—
|
| Changes In Cash |
|
-3.25
-516.82%
|
0.78
+185.51%
|
-0.91
+87.74%
|
-7.43
|
| Effect Of Exchange Rate Changes |
|
0.04
+185.37%
|
-0.04
-612.50%
|
0.01
+109.09%
|
-0.09
|
| Beginning Cash Position |
|
3.38
+27.95%
|
2.64
-25.49%
|
3.54
-67.97%
|
11.06
|
| End Cash Position |
|
0.17
-95.09%
|
3.38
+27.95%
|
2.64
-25.49%
|
3.54
|
| Free Cash Flow |
|
-7.68
+24.26%
|
-10.14
-20.94%
|
-8.38
-9.07%
|
-7.69
|
| Common Stock Issuance |
|
4.53
-59.92%
|
11.30
+160.82%
|
4.33
|
0.00
|
| Interest Received CFI |
|
—
|
—
|
0.18
+263.27%
|
0.05
|
| Issuance Of Capital Stock |
|
4.53
-59.92%
|
11.30
+160.82%
|
4.33
|
0.00
|
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|